Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Famitinib + chemotherapy in non-squamous NSCLC
NCT04619433Phase 3Terminated
- Sponsor
- Hengrui
- Start
- Feb 2021
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of famitinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Hengrui. Primary endpoints: Serum concentrations of Camrelizumab at 42 days, Plasma concentrations of Famitinib at 42 days and 7 more. Started Feb 2021; status: terminated.
02
Drugs
famitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04619433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04619433.